Innovative Journal Journal of Medical Biomedical and Applied Sciences 2277:4939 10 05 A randomized controlled trial to compare the efficacy and safety of glycopyrronium bromide + salmeterol/fluticasone and tiotropium bromide + salmeterol/fluticasone in chronic obstructive pulmonary disease 1 Dr. Rajendra Kumar Assistant Professor, Department of Pharmacology Prasad Institute of Medical Sciences (PIMS), Banthra, Lucknow, U.P (India) Dr. Amrendra Kumar Senior resident, Department of Forensic Medicine & Toxicology AIIMS Patna, Bihar (India). Journal Article https://doi.org/10.15520/ijmhs.v10i03.283 Abstract Objective: To compare the efficacy and safety of glycopyrronium bromide + salmeterol/fluticasone and tiotropium bromide + salmeterol/fluticasone in chronic obstructive pulmonary disease (COPD) in a randomized controlled trial. Methods: This study was an open labeled randomized controlled trial. Patients diagnosed with COPD were included in the study. The patients were divided into 2 groups each consisted 75 patients. Group I- COPD patients on Tiotropium bromide + Salmeterol/Fluticasone; Group II – COPD patient on Glycopyrronium bromide + Salmeterol/Fluticasone. A detailed history and clinical examination was done for each case. Pulmonary Function Test (PFT) was performed at 0, 6 and 12 weeks. Results: There was no significant (p>0.05) difference in the basic characteristics of patients between the groups showing comparability of the groups in terms of basic characteristics. FEV1 was observed to be significantly higher in Group II than Group I at 12 weeks (p=0.03). There was no significant (p>0.05) difference in PEFR between the groups at all the time periods. FEF was observed to be significantly higher in Group II than Group I at 12 weeks (p=0.04). There was no significant (p>0.05) difference in FEV1/FVC between the groups at all the time periods. MVV was found to be significantly higher in Group II compared to Group I at 6 weeks (p=0.03) and 12 weeks (p=0.04). Conclusion: Once-daily GLY demonstrated similar effects to TIO when combined with SAL/FP in patients with moderate and severe COPD. Kerwin, E, Hebert, J, Gallagher, N, Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study, Eur Respir J, 2012, 40, 1106, 1120 White, Patrick, Thornton, Hannah, Pinnock, Hilary, Georgopoulou, Sofia, Booth, Helen P., Overtreatment of COPD with Inhaled Corticosteroids - Implications for Safety and Costs: Cross-Sectional Observational Study, PLoS ONE, 2013, 8, 10, e75221, e75221, 1932-6203, 10.1371/journal.pone.0075221, Public Library of Science (PLoS), https://dx.doi.org/10.1371/journal.pone.0075221 Wang, T, Luo, G, Hu, Y, J. Huazhong Univ. Sci. Technol. Med. Sci, 2011, 31, 614, 614 Buhling, F, Lieder, N, Reisenauer, A, Welte, T, Anti-inflammatory function of tiotropium mediated by suppression of acetylcholine-induced release of chemotactic activity, Eur Respir J, 2004, 24, 48 Ranu, H, Wilde, M, Madden, B, Pulmonary function tests. The Ulster medical journal, 2011, 80, 84, 90 Peter, A, Frith, Philip, J, Thompson, Rajeev, Ratnavadivel, Catherina L, Chang, Peter, Bremner, Peter, Day, Christina, Frenzel, Nicol Kurstjens, the Glisten Study Group. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study-a randomised controlled trial. l, Thorax, 2015, 70, 519, 527 Lin, S H, Kuo, P H, Kuo, S H, Yang, P C, Severity staging of chronic obstructive pulmonary disease: differences in pre- and post-bronchodilator spirometry, Yonsei medical journal, 2009, 50, 5, 672, 676 Diaz-Guzman, Enrique, Mannino, David M., Epidemiology and Prevalence of Chronic Obstructive Pulmonary Disease, Clinics in Chest Medicine, 2014, 35, 1, 7, 16, 0272-5231, 10.1016/j.ccm.2013.10.002, Elsevier BV, https://dx.doi.org/10.1016/j.ccm.2013.10.002 Li, Y, Li, Y H, Luo, Y W, Effects of inhaled short-acting bronchodilators on diaphragm function and neural respiratory drive during maximal isocapnic ventilation in patients with chronic obstructive pulmonary disease, J Southern Med Univ, 2016, 36, 2, 232, 237 Kottakis, John, Cioppa, Giovanni Della, Creemers, Jacques, Greefhorst, Louis, Leclerc, Violette, Pistelli, Riccardo, Overend, Tim, Till, Denise, Rapatz, Günter, LeGros, Vincent, Bouros, Demosthenes, Siafakas, Nikolaos, Faster Onset of Bronchodilation with Formoterol than with Salmeterol in Patients with Stable, Moderate-Severe Copd: Results of a Randomized, Double-Blind Clinical Study, Canadian Respiratory Journal, 2002, 9, 2, 107, 115, 1198-2241, 10.1155/2002/604092, Hindawi Limited, https://dx.doi.org/10.1155/2002/604092 Min, Xiang, Effect of tiotropium bromide combined with salmeterol fluticasone inhalation on airway function and airway inflammation in patients with moderate-severe stable COPD, Journal of Hainan Medical University, 2016, 22, 23, 24, 27 Force, Rex W., Evidence-Based Medicine and Information Mastery: Application for Acute Gastrointestinal Conditions, Pharmacotherapy, 2003, 23, 61S, 67S, 0277-0008, Wiley, 10.1592/phco.23.13.61s.31927, https://dx.doi.org/10.1592/phco.23.13.61s.31927 Sykes, David A., Dowling, Mark R., Leighton-Davies, Juliet, Kent, Toby C., Fawcett, Lindsay, Renard, Emilie, Trifilieff, Alexandre, Charlton, Steven J., The Influence of Receptor Kinetics on the Onset and Duration of Action and the Therapeutic Index of NVA237 and Tiotropium, Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 2, 520, 528, 0022-3565, 1521-0103, 10.1124/jpet.112.194456, American Society for Pharmacology & Experimental Therapeutics (ASPET), https://dx.doi.org/10.1124/jpet.112.194456 Chapman, K R, Beeh, K M, Beier, J, A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study, BMC Pulm Med, 2014, 14, 4, 4 Kulynychmiskiv, Mariana, Ostrovskyy, Mykola, Ostrovska, Kseniia, Varunkiv, Oleksandr, Savelikhina, Iryna, Tiotropium bromide: Efficacy and safety in complex treatment of COPD, European Respiratory Journal, 2017, 50 Kew, Kayleigh M, Dias, Sofia, Cates, Christopher J, Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis, Cochrane Database of Systematic Reviews, 2014, 3, 1465-1858, 10.1002/14651858.cd010844.pub2, Wiley, https://dx.doi.org/10.1002/14651858.cd010844.pub2 Miller, M R, Crapo, R, Hankinson, J, General considerations for lung function testing. The European respiratory journal, 2005, 26, 153, 161 Bourbeau, J., Christodoulopoulos, P., Maltais, F., Yamauchi, Y., Olivenstein, R., Hamid, Q., Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial, Thorax, 2007, 62, 11, 938, 943, 0040-6376, 10.1136/thx.2006.071068, BMJ, https://dx.doi.org/10.1136/thx.2006.071068 The Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2014